Close Menu

NEW YORK (GenomeWeb) – Fluidigm has announced that it has entered a co-marketing agreement with Genomenon to offer evidence-based genomic panel design services for translational and clinical disease researchers.

According to the partners, researchers will be able to expedite the design of disease-specific next-generation sequencing, genotyping, and real-time PCR panels using Fluidigm's automated microfluidic systems.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.